Filtered By:
Drug: Tamoxifen

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 50 results found since Jan 2013.

Cerebral venous thrombosis in a breast cancer patient taking tamoxifen: Report of a case
Conclusion Clinicians should warn about the possibility of thromboembolic complications with tamoxifen.
Source: International Journal of Surgery Case Reports - November 29, 2014 Category: Surgery Source Type: research

Risk-Benefit Profiles of Women Using Tamoxifen for Chemoprevention
Conclusions: While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit, substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention.
Source: JNCI - December 3, 2014 Category: Cancer & Oncology Authors: Nichols, H. B., DeRoo, L. A., Scharf, D. R., Sandler, D. P. Tags: Article Source Type: research

Microvascular Lesions by Estrogen-Induced ID3: Its Implications in Cerebral and Cardiorenal Vascular Disease
We present evidence for how ID3 overexpression in endothelial cells contributes to the development of an estrogen-induced neovascular phenotype with an additional focus on Pyk2 kinase. Our data showed that ID3 overexpression increased neovascularization, cell migration, and spheroid growth of human cerebral microvascular endothelial cells, hCMEC/D3. ID3-overexpressing cells showed significant estrogen-induced G2/M phase transition. Estrogen treatment increased both ID3 phosphorylation; total protein that was inhibited by tamoxifen, and Pyk2-mediated estrogen-induced ID3 mRNA expression. These findings suggest that Pyk2 sig...
Source: Journal of Molecular Neuroscience - February 7, 2015 Category: Neuroscience Source Type: research

Abstract 1341: Endocrine deprivation therapy increases the sensitivity of breast cancer cells to T cell-mediated lysis independently of estrogen receptor or androgen receptor status
Estrogen deprivation therapy has been used as the first line adjuvant hormonal therapy for breast cancer for over 20 years. Tamoxifen, the first drug discovered to inhibit estrogen receptor signaling, is used to treat premenopausal women with estrogen receptor positive tumors. Although tamoxifen can be therapeutic in most women with estrogen receptor positive tumors, some women do not respond and others eventually develop resistance. In addition, tamoxifen has minimal effect on the growth of estrogen receptor negative tumors, including triple negative breast cancer, which has the poorest prognosis. Furthermore, prolonged a...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kwilas, A. R., Ardiani, A., Gameiro, S. R., Hodge, J. W. Tags: Immunology Source Type: research

Update on Breast Cancer Risk Reduction Therapy
Abstract In women at increased risk of breast cancer age ≥35 years, the selective estrogen receptor modulator (SERM) tamoxifen should be discussed as an option to reduce the risk of estrogen receptor (ER)-positive breast cancer. In postmenopausal women, raloxifene, anastrozole, and exemestane should also be discussed as options for breast cancer risk reduction. Risk reduction with SERMs continues for at least 10 years in both premenopausal and postmenopausal women. Tamoxifen is not recommended for women with a history of deep vein thrombosis, pulmonary embolus, stroke, transient ischemic attack, or during prol...
Source: Current Breast Cancer Reports - July 19, 2016 Category: Cancer & Oncology Source Type: research

Estrogens and Coronary Artery Disease: New Clinical Perspectives.
Abstract In premenopausal women, endogenous estrogens are associated with reduced prevalence of arterial hypertension, coronary artery disease, myocardial infarction, and stroke. Clinical trials conducted in the 1990s such as HERS, WHI, and WISDOM have shown that postmenopausal treatment with horse hormone mixtures (so-called conjugated equine estrogens) and synthetic progestins adversely affects female cardiovascular health. Our understanding of rapid (nongenomic) and chronic (genomic) estrogen signaling has since advanced considerably, including identification of a new G protein-coupled estrogen receptor (GPER),...
Source: Advances in Pharmacology - July 29, 2016 Category: Drugs & Pharmacology Authors: Meyer MR, Barton M Tags: Adv Pharmacol Source Type: research

Conditional knockout of activin like kinase-1 (ALK-1) leads to heart failure without maladaptive remodeling
AbstractActivin like kinase-1 (AlK-1) mediates signaling via the transforming growth factor beta (TGF β) family of ligands. AlK-1 activity promotes endothelial proliferation and migration. Reduced AlK-1 activity is associated with arteriovenous malformations. No studies have examined the effect of global AlK-1 deletion on indices of cardiac remodeling. We hypothesized that reduced levels of AlK-1 p romote maladaptive cardiac remodeling. To test this hypothesis, we employed AlK-1 conditional knockout mice (cKO) harboring the ROSA26-CreER knock-in allele, whereby a single dose of intraperitoneal tamoxifen triggered ubiquito...
Source: Heart and Vessels - February 16, 2017 Category: Cardiology Source Type: research

Abstract PD4-07: Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study
Conclusions: The occurrence of MI is very low in this cohort (4.4%), reassuring the clinicians that the older adults with comorbidities may not be at a higher risk of MI with adjuvant endocrine therapy. However, the confidence interval for the hazard ratio of AIs vs Tamoxifen is very wide, indicating that a larger sample may be needed for the power of the study to be conclusive.Citation Format: Kamaraju S, Smith E, Shi Y, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population study [abstract]. In: Proceedings of the Thirty-Ninth Annual C...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: S Kamaraju, E Smith, Y Shi, P Laud, J Neuner Tags: Poster Discussion Abstracts Source Type: research

Abstract P2-01-23: Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+(R))
Patients with breast cancer (BC) and those at high risk for BC are often reluctant to initiate Tamoxifen (Tam) due to potential adverse events (AEs) such as deep vein thrombosis (DVT), pulmonary embolus (PE), acute ischemic stroke (AIS), myocardial infarction (MI) and endometrial cancer (EC). Some decline this life saving therapy due to fear of AEs. AE rates from RCTs are low, but AE rates in the general population are not well documented.Methods: The MarketScanR database (2010-2013) was searched for patients aged 30-64 with a prescription of Tam active for more than 120 days. Patients with prior DVT, PE, AIS, MI or EC wer...
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: K Hannebicque, L Boulanger, E Bogart, S Giard, MP Chauvet, JL Houpeau Tags: Poster Session Abstracts Source Type: research

Mangosteen: The Cancer-Fighting Superfruit
  If you're a woman with a family history of breast cancer, your doctor may recommend you start taking a toxic chemo drug like tamoxifen to lower your risk of developing the disease. Even if you have no signs or symptoms of cancer. Tamoxifen is what's known as a chemopreventive agent. That's a fancy phrase that means it's something that prevents cancer from forming. But its track record isn't all that impressive. Trials found that for every 1,000 women who take the drugs, only 21 to 35 cases of cancer would be prevented. And the side effects are downright terrifying. Bone pain, blood clots, increas...
Source: Al Sears, MD Natural Remedies - March 23, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Endothelial Cell-Specific Inactivation of TSPAN12 (Tetraspanin 12) Reveals Pathological Consequences of Barrier Defects in an Otherwise Intact Vasculature.
Conclusions- This study establishes mice with late endothelial cell-specific loss of Tspan12 as a model to study pathological consequences of BRB impairment in an otherwise intact vasculature. PMID: 30354230 [PubMed - in process]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - October 26, 2018 Category: Cardiology Authors: Zhang C, Lai MB, Pedler MG, Johnson V, Adams RH, Petrash JM, Chen Z, Junge HJ Tags: Arterioscler Thromb Vasc Biol Source Type: research

Microglial-specific depletion of TAK1 is neuroprotective in the acute phase after ischemic stroke
AbstractTransforming growth factor- β-activated kinase 1 (TAK1) is upregulated after cerebral ischemia and contributes to an aggravation of brain injury. TAK1 acts as a key regulator of NF-ΚB and the MAP kinases JNK and p38 and modulates post-ischemic neuroinflammation and apoptosis. Microglia are the main TAK1-expressing immunocomp etent cells of the brain. However, little is known about the function and regulation of microglial TAK1 after cerebral ischemia. Tamoxifen-dependent conditional depletion of TAK1 in microglial cells was induced inCx3cr1creER-Tak1fl/fl mice. ThecreER-negativeTak1fl/fl mice and vehicle-treated ...
Source: Journal of Molecular Medicine - May 6, 2020 Category: Molecular Biology Source Type: research

Cancers, Vol. 13, Pages 2254: Adjuvant Hormonotherapy and Cardiovascular Risk in Post-Menopausal Women with Breast Cancer: A Large Population-Based Cohort Study
Conclusions: Adjuvant therapy with AI in breast cancer women aged more than 50 years is associated with increased risk of heart failure and combined CV events.
Source: Cancers - May 8, 2021 Category: Cancer & Oncology Authors: Matteo Franchi Roberta Tritto Luigi Tarantini Alessandro Navazio Giovanni Corrao Tags: Article Source Type: research

Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study
CONCLUSION: Our results indicate an increased risk for ischemic heart disease and arrhythmia in patients treated for more than four years with AIs. This should be considered in the risk-benefit assessment concerning endocrine therapy.PMID:34265496 | DOI:10.1016/j.breast.2021.07.004
Source: Breast - July 15, 2021 Category: Cancer & Oncology Authors: Maria Sund Miguel Garcia-Argibay Hans Garmo Johan Ahlgren Anna-Karin Wennstig Irma Fredriksson Henrik Lindman Antonis Valachis Source Type: research